Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

American Journal of Hematology

Volumn 52, Issue 1, 1996, Pages 42-46

  Nand, Sucha ^a   Stock, Wendy ^b   Godwin, John ^b   Fisher, Susan Gross ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b NONE

Author keywords

Essential thrombocytosis; Hydroxyurea; Myelofibrosis with myeloid metaplasia; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; HYDROXYUREA; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ACUTE DISEASE; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BUSULFAN; CELL TRANSFORMATION, NEOPLASTIC; CHLORAMBUCIL; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYUREA; INCIDENCE; INTERFERON-ALPHA; LEUKEMIA; LEUKEMIA, RADIATION-INDUCED; MALE; MELPHALAN; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; PHOSPHORUS RADIOISOTOPES; POLYCYTHEMIA VERA; PRELEUKEMIA; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES; RISK; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0030011932     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6     Document Type: Article

References (25)

1. Hoffman R, Wasserman LR: Natural history and management of polycythemia vera. Adv Intern Med 24:255-285, 1979.
2. Meytes D, Katz D, Ramot B: Preleukemia and leukemia in polycythemia vera. Blood 47:237-241, 1976.
3. Rosenthal DS, Moloney WC: Occurrence of acute leukemia in myeloproliferative disorders. Br J Haematol 36:373-382, 1977.
4. Berk PD, Goldbert JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciola AV, Wasserman LR: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441-447, 1981
5. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR: Long term management of polycythemia with hydroxyurea. A progress report. Semin Hematol 23.167-171, 1987.
6. Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB, Knospe WH, Laszlo J, Mack K, Berk PD, Wasserman LR: Treatment of polycythemia with hydroxyurea. Am J Hematol 17:329-334, 1984.
7. Sharon R, Tatarsky I, Ben-Arieh Y: Treatment of polycythemia with hydroxyurea. Cancer 57:718-720, 1986.
8. West W: Hydroxyurea in the treatment of polycythemia vera. South Med J 80:323-327, 1987.
9. Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664, 1995.
10. Berk PD, Goldberg JD, Donovan PB, Fruchtmen SM, Berlin NI, Wasserman LR: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23.132-143, 1986.
11. Silver RT: Interferon alpha 2 b: A new treatment for polycythemia vera. Ann Intern Med 119:1091-1092, 1993.
12. Silver RT: A new treatment for polycythemia vera: Recombinant interferon alpha. Blood 76:664-665, 1990.
13. Hoffman R, Silverstein MN. Agnogenic myeloid metaplasia: In Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds), "Hematology. Basic Principles and Practice." New York: Churchill Livingstone, 1995, pp 1160-1174.
14. Hoffman R, Silverstein MN, Hromas R. Primary thrombocythemia. In Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds), "Hematology. Basic Principles and Practice." New York: Churchill Livingstone, 1995, pp 1174-1184.
15. Hehlmann R, Jahn M, Baumann B, Kopeke W: Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61.2487-2493, 1988.
16. Schimke RT, Sherwood SW, Hill AB, Johnson RN: Overreplication and recombination of DNA in higher eukaryotes. Potential consequences and biological implications Proc Natl Acad Sci USA 83:2157-2161, 1986
17. Berlin NI Diagnosis and classification of polycythemia vera Semin Hematol 12:339-351, 1975
18. Chievitz E, Thiede T: Complications and causes of death in polycythemia vera Acta Med Scand 172:513-523, 1962
19. Wasserman LR, Balcerzak SP, Berk PD: Influence of therapy on cause of death in polycythemia vera Trans Assoc Am Physicians 94:30-38, 1981.
20. Modan B, Lilienfeld AM: Polycythemia vera and leukemia - the role of radiation treatment. A study of 1.222 patients Medicine (Baltimore) 44:305-344, 1965.
21. European Organization for Research on Treatment of Cancer, Leukemia and Hematosarcoma Co-operative Group: Treatment of polycythemia vera by radioactive phosphorus or busulfan. A randomized trial. Br J Cancer 44:74-80, 1981.
22. Hehlman R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B, for German CML Study Group: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia. Prolongation of survival by hydroxyurea. Blood 83:398-407, 1993.
23. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
24. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med 332:1317-1322, 1995.
25. Nand S, Messmore H, Fisher SG, Bird ML, Schultz W, Fisher RI: Leukemic transformation in polycythemia vera. Analysis of risk factors. Am J Hematol 34:32-36, 1990.